Anda Vlad

Dr. Anda Vlad


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
SGShannon Grabosch
Shannon Grabosch
MBMirna Bulatovic
Mirna Bulatovic
FZFeitianzhi Zeng
Feitianzhi Zeng
TMTianzhou Ma
Tianzhou Ma
LZLixin Zhang
Lixin Zhang
AVAnda Vlad
Anda Vlad

30 November 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SSSwati Suryawanshi
Swati Suryawanshi
XHXin Huang
Xin Huang
EEEsther Elishaev
Esther Elishaev
RBRaluca A. Budiu
Raluca A. Budiu
LZLixin Zhang
Lixin Zhang
AVAnda Vlad
Anda Vlad
Purpose: Mechanisms of immune dysregulation associated with advanced tumors are relatively well understood. Much less is known about the role of immune effectors against cancer precursor lesions. Endometrioid and clear-cell ovarian tumors partly derive from endometriosis, a commonly diagnosed chronic inflammatory disease. We performed here a comprehensive immune gene expression analysis of pelvic inflammation in endometriosis and endometriosis-associated ovarian cancer (EAOC). Experimental Design: RNA was extracted from 120 paraffin tissue blocks comprising of normal endometrium (n = 32), benign endometriosis (n = 30), atypical endometriosis (n = 15), and EAOC (n = 43). Serous tumors (n = 15) were included as nonendometriosis-associated controls. The immune microenvironment was profiled using Nanostring and the nCounter GX Human Immunology Kit, comprising probes for a total of 511 immune genes. Results: One third of the patients with endometriosis revealed a tumor-like inflammation profile, suggesting that cancer-like immune signatures may develop earlier, in patients classified as clinically benign. Gene expression analyses revealed the complement pathway as most prominently involved in both endometriosis and EAOC. Complement proteins are abundantly present in epithelial cells in both benign and malignant lesions. Mechanistic studies in ovarian surface epithelial cells from mice with conditional (Cre-loxP) mutations show intrinsic production of complement in epithelia and demonstrate an early link between Kras- and Pten-driven pathways and complement upregulation. Downregulation of complement in these cells interferes with cell proliferation. Conclusions: These findings reveal new characteristics of inflammation in precursor lesions and point to previously unknown roles of complement in endometriosis and EAOC. Clin Cancer Res; 20(23); 6163–74. ©2014 AACR.

19 August 2009 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
AVAnda Vlad
Anda Vlad
RBRaluca A. Budiu
Raluca A. Budiu
DLDiana E. Lenzner
Diana E. Lenzner
YWYun Wang
Yun Wang
JTJulia A. Thaller
Julia A. Thaller
RERobert Edwards
Robert Edwards

2 April 2011 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
RBRaluca A. Budiu
Raluca A. Budiu
GMGina Mantia-Smaldone
Gina Mantia-Smaldone
EEEsther Elishaev
Esther Elishaev
TCTianjiao Chu
Tianjiao Chu
JTJulia Thaller
Julia Thaller
AVAnda Vlad
Anda Vlad

18 January 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BOBrian Orr
Brian Orr
HMHaider Mahdi
Haider Mahdi
YFYusi Fang
Yusi Fang
MSMary Strange
Mary Strange
IUIbrahim Uygun
Ibrahim Uygun
AVAnda Vlad
Anda Vlad
Purpose: Increased prevalence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts positive outcomes in patients with epithelial ovarian cancer (EOC), whereas the regulatory T cells (Treg) predict poor outcomes. Guided by the synergistic activity of TLR3 ligands, IFNα, and COX-2 blockers in selectively enhancing CTL-attractants but suppressing Treg-attractants, we tested a novel intraperitoneal chemoimmunotherapy combination (CITC), to assess its tolerability and TME-modulatory impact in patients with recurrent EOC. Patients and Methods: Twelve patients were enrolled in phase I portion of the trial NCT02432378, and treated with intraperitoneal cisplatin, intraperitoneal rintatolimod (dsRNA, TLR3 ligand), and oral celecoxib (COX-2 blocker). Patients in cohorts 2, 3, and 4 also received intraperitoneal IFNα at 2, 6, and 18 million units (MU), respectively. Primary objectives were to evaluate safety, identify phase 2 recommended dose (P2RD), and characterize changes in the immune TME. Peritoneal resident cells and intraperitoneal wash fluid were profiled via NanoString and Meso Scale Discovery (MSD) multiplex assay, respectively. Results: The P2RD of IFNα was 6 MU. Median progression-free survival and overall survival were 8.4 and 30 months, respectively. Longitudinal sampling of the peritoneal cavity via intraperitoneal washes demonstrated local upregulation of IFN-stimulated genes (ISG), including CTL-attracting chemokines (CXCL-9, -10, -11), MHC I/II, perforin, and granzymes. These changes were present 2 days after chemokine modulation and subsided within 1 week. Conclusions: The chemokine-modulating intraperitoneal-CITC is safe, tolerable, and associated with ISG changes that favor CTL chemoattraction and function. This combination (plus DC vaccine) will be tested in a phase II trial. See related commentary by Aranda et al., p. 1993

11 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EHErin G. Hartnett
Erin G. Hartnett
JKJulia Knight
Julia Knight
MRMackenzy Radolec
Mackenzy Radolec
Ronald BuckanovichRonald Buckanovich
Ronald Buckanovich
RERobert Edwards
Robert Edwards
AVAnda Vlad
Anda Vlad
New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials.